Business Description
Exagen Inc
NAICS : 541380
SIC : 8071
ISIN : US30068X1037
Share Class Description:
XGN: Ordinary SharesDescription
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.54 | |||||
| Equity-to-Asset | 0.4 | |||||
| Debt-to-Equity | 1.05 | |||||
| Debt-to-EBITDA | -1.24 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -6 | |||||
| Beneish M-Score | -3.08 | |||||
| WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -3.7 | |||||
| 3-Year EBITDA Growth Rate | -0.1 | |||||
| 3-Year EPS without NRI Growth Rate | -0.5 | |||||
| 3-Year FCF Growth Rate | 9.1 | |||||
| 3-Year Book Growth Rate | -26.2 | |||||
| Future 3-5Y Total Revenue Growth Rate | 11.5 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 43.74 | |||||
| 9-Day RSI | 40.05 | |||||
| 14-Day RSI | 39.22 | |||||
| 6-1 Month Momentum % | -10.17 | |||||
| 12-1 Month Momentum % | -42.59 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.02 | |||||
| Quick Ratio | 4.02 | |||||
| Cash Ratio | 3.07 | |||||
| Days Sales Outstanding | 76.7 | |||||
| Days Payable | 34.84 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -10.4 | |||||
| Shareholder Yield % | 31.11 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 56.06 | |||||
| Operating Margin % | -43.46 | |||||
| Net Margin % | -45.08 | |||||
| FCF Margin % | -29.1 | |||||
| ROE % | -73.8 | |||||
| ROA % | -34.08 | |||||
| ROIC % | -115.53 | |||||
| ROC (Joel Greenblatt) % | -113.98 | |||||
| ROCE % | -35.77 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 0.48 | |||||
| PB Ratio | 1.05 | |||||
| Price-to-Tangible-Book | 1.05 | |||||
| EV-to-EBIT | -0.53 | |||||
| EV-to-Forward-EBIT | -0.53 | |||||
| EV-to-EBITDA | -0.59 | |||||
| EV-to-Forward-EBITDA | -1.11 | |||||
| EV-to-Revenue | 0.21 | |||||
| EV-to-Forward-Revenue | 0.21 | |||||
| EV-to-FCF | -0.74 | |||||
| Price-to-Net-Current-Asset-Value | 1.75 | |||||
| Price-to-Net-Cash | 10.77 | |||||
| Earnings Yield (Greenblatt) % | -188.68 | |||||
| FCF Yield % | -62.92 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers